Sugi Predict

Sugi Predict / Compounds / SCHEMBL4816031

SCHEMBL4816031

SCHEMBL4816031

COCCOc1ccc2[nH]c(C(=O)O)cc2c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.64
▸ ALDH1A1 P00352 4/20 0.64
▸ HPGD P15428 3/20 0.64
▸ CYP1A2 P05177 2/20 0.64
▸ CYP2C9 P11712 2/20 0.64
▸ HSD17B10 Q99714 2/20 0.64
▸ SRD5A2 P31213 1/20 0.64
▸ KMT2A Q03164 2/20 0.58
▸ PDGFRB P09619 6/20 0.55
▸ PDGFRA P16234 6/20 0.55
▸ XDH P47989 1/20 0.54
▸ MAPT P10636 1/20 0.54
▸ PLA2G4A P47712 1/20 0.54
▸ PIN1 Q13526 1/20 0.54
▸ FLT3 P36888 2/20 0.53
▸ SMAD3 P84022 1/20 0.51
▸ TSHR P16473 2/20 0.51
▸ LMNA P02545 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17775020 0.96 KDM4E (0.60) KDM4EALDH1A1HPGDCYP1A2CYP2C9
SCHEMBL17775016 0.96 KDM4E (0.60) KDM4EALDH1A1HPGDCYP1A2CYP2C9
SCHEMBL17775017 0.96 KDM4E (0.60) KDM4EALDH1A1HPGDCYP1A2CYP2C9
SCHEMBL17775018 0.96 KDM4E (0.60) KDM4EALDH1A1HPGDCYP1A2CYP2C9
SCHEMBL17775023 0.96 KDM4E (0.60) KDM4EALDH1A1HPGDCYP1A2CYP2C9
SCHEMBL17775019 0.96 KDM4E (0.60) KDM4EALDH1A1HPGDCYP1A2CYP2C9
SCHEMBL13174431 0.93 KDM4E (0.62) KDM4EALDH1A1HPGDCYP1A2CYP2C9
SCHEMBL5268277 0.89 FLT3 (0.53) KDM4EALDH1A1HPGDCYP1A2CYP2C9
SCHEMBL6422585 0.88 CFD (0.56) KDM4EALDH1A1HPGDCYP1A2CYP2C9
SCHEMBL6422580 0.88 PDGFRB (0.54) KDM4EALDH1A1HPGDCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208491-B2 N-monoacylated o-phenylenediamines HOFFMANN-LA ROCHE INC. (US) 2007-04-24 — — US claimed
US-20040157841-A1 inhibition of histone deacetylase; for inhibiting cell proliferation; cancer therapy HOFFMANN-LA ROCHE INC. 2004-08-12 — — US claimed
CN-113439084-B Sesqui-carcinomycin analogue 奥克兰联合服务有限公司 2025-02-25 — — CN disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 — — US disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 — — US disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 — — US disclosed
US-20220098215-A1 DUOCARMYCIN ANALOGUES AUCKLAND UNISERVICES LIMITED (NZ) 2022-03-31 — — US disclosed
EP-3917933-A1 DUOCARMYCIN ANALOGUES Auckland Uniservices Limited (NZ) 2021-12-08 — — EP disclosed
EP-3500574-B1 SECO-CYCLOPROPAPYRROLOINDOLE COMPOUNDS, ANTIBODY-DRUG CONJUGATES THEREOF, AND METHODS OF MAKING AND USE BRISTOL MYERS SQUIBB CO (US) 2021-11-24 — — EP disclosed
CN-113439084-A Duocarmycin analogs 奥克兰联合服务有限公司 2021-09-24 — — CN disclosed
WO-2020157662-A1 DUOCARMYCIN ANALOGUES AUCKLAND UNISERVICES LIMITED (NZ) 2020-08-06 — — WO disclosed
EP-1656348-B1 ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE AXYS PHARM INC (US) 2007-02-07 — — EP disclosed
EP-1656348-A1 ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE AXYS PHARMACEUTICALS, INC. (US) 2006-05-17 — — EP disclosed
WO-2005118584-A2 SAFRAMYCIN ANALOGS AS THERAPEUTIC AGENTS IN THE TREATMENT OF CANCER AXYS PHARMACEUTICALS, INC. (US) 2005-12-15 — — WO disclosed
EP-1594857-A2 N-MONOACYLATED O-PHENYLENEDIAMINES AS ANTI-CANCER AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2005-11-16 — — EP disclosed
US-20050131018-A1 Acetylene derivatives as inhibitors of histone deacetylase AXYS PHARMACEUTICALS, INC. (US) 2005-06-16 — — US disclosed
WO-2005019174-A1 ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE AXYS PHARMACEUTICALS, INC. (US) 2005-03-03 — — WO disclosed
WO-2005019174-A1 ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE AXYS PHARMACEUTICALS, INC. (US) 2005-03-03 — — WO disclosed
WO-2004069133-A2 N-MONOACYLATED O-PHENYLENEDIAMINES AS ANTI -CANCER AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2004-08-19 — — WO disclosed
US-20040157841-A1 inhibition of histone deacetylase; for inhibiting cell proliferation; cancer therapy HOFFMANN-LA ROCHE INC. 2004-08-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF COL1A1, COL2A1, COL14A1 KDM4E 1980/4885ALDH1A1 1196/4885HPGD 2406/4885
US-20220098215-A1 DUOCARMYCIN ANALOGUES TOP2A, TOP2B, MUS81 KDM4E 406/4885ALDH1A1 2426/4885HPGD 2775/4885
US-20040157841-A1 inhibition of histone deacetylase; for inhibiting cell proliferation; cancer therapy HDAC1, HDAC11, HDAC7 KDM4E 137/4885ALDH1A1 189/4885HPGD 755/4885
US-20050131018-A1 Acetylene derivatives as inhibitors of histone deacetylase HDAC1, HDAC10, HDAC2 KDM4E 726/4885ALDH1A1 429/4885HPGD 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.